164 related articles for article (PubMed ID: 12614466)
1. The impact of prior hepatitis B virus infection on liver histology and the response to interferon therapy in chronic hepatitis C.
Myers RP; Thibault V; Poynard T
J Viral Hepat; 2003 Mar; 10(2):103-10. PubMed ID: 12614466
[TBL] [Abstract][Full Text] [Related]
2. Effect of Previous Exposure to HBV on Liver Histology and Treatment Response in CHC Patients.
Khan HA; Umar M; Hamama-tul-Bushra ; Ahmed M; Ambreen S
J Coll Physicians Surg Pak; 2015 Jul; 25(7):498-500. PubMed ID: 26208552
[TBL] [Abstract][Full Text] [Related]
3. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
[TBL] [Abstract][Full Text] [Related]
4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
5. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
6. The impact of previous HBV infection on the course of chronic hepatitis C.
De Maria N; Colantoni A; Friedlander L; Leandro G; Idilman R; Harig J; Van Thiel DH
Am J Gastroenterol; 2000 Dec; 95(12):3529-36. PubMed ID: 11151889
[TBL] [Abstract][Full Text] [Related]
7. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease.
Cacciola I; Pollicino T; Squadrito G; Cerenzia G; Orlando ME; Raimondo G
N Engl J Med; 1999 Jul; 341(1):22-6. PubMed ID: 10387938
[TBL] [Abstract][Full Text] [Related]
8. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
9. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
11. Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C.
Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():327-34. PubMed ID: 27051280
[TBL] [Abstract][Full Text] [Related]
12. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
13. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
Toyoda H; Kumada T; Tada T; Murakami Y
J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
[TBL] [Abstract][Full Text] [Related]
14. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
[TBL] [Abstract][Full Text] [Related]
15. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.
Ikeda K; Marusawa H; Osaki Y; Nakamura T; Kitajima N; Yamashita Y; Kudo M; Sato T; Chiba T
Ann Intern Med; 2007 May; 146(9):649-56. PubMed ID: 17470833
[TBL] [Abstract][Full Text] [Related]
16. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
[TBL] [Abstract][Full Text] [Related]
17. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
18. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
19. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
20. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
